Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
oncolytic virus
Biotech
Candel burns bright as phase 3 cancer win sends stock up 200%
Candel reported a 14.5% relative improvement in disease-free survival, an endpoint that looked at cancer recurrence or death from any cause.
Nick Paul Taylor
Dec 11, 2024 9:49am
Transgene's viral cancer vaccine flunks midphase test
Oct 14, 2024 4:59am
CG sets new bar in bladder cancer, months after huge IPO
May 3, 2024 11:23am
CG Oncology plans IPO ahead of phase 3 bladder cancer readout
Jan 3, 2024 8:25am
Candel’s flame dims as layoffs hit 50% of the team
Nov 28, 2023 11:23am
CG raises $105M crossover round to fund phase 3 cancer trial
Aug 2, 2023 9:07am
